Tracking Biologics Along the Silk Road

Trial Profile

Tracking Biologics Along the Silk Road

Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Golimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms HARIR
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 31 Oct 2017 Planned number of patients changed from 338 to 150.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top